Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a Phase 2 clinical study ...

Breyanzi offers a personalized treatment option delivered as a one-time infusion that provides deep and durable responses for patients with relapsed or refractory CLL or SLL who have historically had ...

Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL) This is an ASCO Meeting Abstract from the 2004 ...

Acalabrutinib (Calquence) yielded high efficacy and a manageable safety profile for the treatment of chronic lymphocytic leukemia (CLL) in older and/or frail patients, according to findings from the ...

Combination Therapies. Zanubrutinib Plus Venetoclax. Fixed-duration therapies with Bruton's tyrosine kinase (BTK) inhibitors and BCL2 inhibitors are emerging as a new treatment op ...

Rituxan targets B-cells in CLL by engaging immune cells for antibody-dependent phagocytosis and inducing cell lysis. Autoimmune hemolytic anemia involves the immune system mistakenly destroying red ...

The FDA has approved Genentech’s Gazyva (obinutuzumab) for the treatment of lupus nephritis in adults, according to a news release published today. Gazyva is the first and only anti-CD20 monoclonal ...

A review of machine learning (ML) models developed to support the management of chronic lymphocytic leukemia (CLL) have demonstrated positive outcomes, including accurate diagnosis and improved work ...

Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810 Sixty-nine ...

Nanopore sequencing offers comparable accuracy to short-read NGS for IGH clonotyping in CLL, with advantages in cost and laboratory footprint. The study confirms reliable somatic hypermutation status ...